Sanyal Biotechnology

Sanyal Biotechnology is a contract research organization based in Norfolk, Virginia, with a team of 5 employees. The company generates approximately $2.5 million in annual revenue. Sanyal Biotechnology specializes in pre-clinical small animal model screening for drugs, particularly focusing on liver disease and related metabolic syndrome comorbidities. They serve clients seeking a more physiologically relevant small animal model for their research. Sanyal Biotechnology's proprietary isogenic mouse model, the DIAMONDᵀᴹ mouse, develops non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) solely due to a Western diet. This model accurately reflects the progression of human liver disease associated with metabolic syndrome, exhibiting symptoms like obesity, dyslipidemia, insulin resistance, cirrhosis, and hepatocellular carcinoma (HCC). To meet client needs, Sanyal Biotechnology develops customized studies to screen compounds based on specific endpoints. The company offers comprehensive data interpretation and a range of core services beyond histopathology. For inquiries, visit Sanyal Biotechnology's website at sanyalbio.com. All studies are conducted in an AAALAC accredited and GLP compliant environment.